A joint China State Institute of Pharmaceutical Industry and Shanghai Institute of Pharmaceutical Industry Co. Ltd. patent divulges new mitochondrial pyruvate carrier (MPC) inhibitors potentially useful for the treatment of alopecia, diabetes, metabolic and inflammatory disorders.
Almirall SA and Certest Biotec SL, through its Certest Pharma division, have signed a strategic research collaboration and licensing agreement to jointly discover and clinically develop treatments for rare dermatologic diseases and recurrent cutaneous conditions.
Sanofi SA will not seek approval of amlitelimab in atopic dermatitis (AD) as previously planned, stating that the OX40-ligand monoclonal antibody “would not represent a meaningful improvement to the standard of care” for patients with moderate to severe disease. The company said the decision, which marks an about-face as Sanofi had been looking to amlitelimab as a possible successor to its Regeneron Pharmaceuticals Inc.-partnered blockbuster AD drug Dupixent (dupilumab), comes as part of an ongoing assessment of the pipeline.
